Xtandi licensed for pre-chemotherapy use

The oral androgen receptor antagonist Xtandi (enzalutamide) is now licensed for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic and in whom chemotherapy is not yet indicated.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Vitamin D supplements could nearly halve the rate of...

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Ertugliflozin (Steglatro) is a sodium glucose co-transporter...